Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] ab215203 is a rabbit monoclonal antibody that is used in cleaved N-terminal GSDMD western blotting. Suitable for human samples.
- Recombinant format for unrivaled batch-batch consistency: no need for same-lot requests
- Antibody clone EPR20829-408 is cited in over 170 publications
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
WB | IHC-P | |
---|---|---|
Human | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes We recommend using a higher sensitive ECL substrate to increase the band intensity. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Gasdermin-DPrecursor of a pore-forming protein that plays a key role in host defense against pathogen infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27281216). This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-D, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:26375003, PubMed:26375259, PubMed:27281216).Gasdermin-D, N-terminalPromotes pyroptosis in response to microbial infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27418190, PubMed:28392147, PubMed:32820063, PubMed:34289345, PubMed:38040708, PubMed:38530158, PubMed:38599239). Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1, CASP4 or CASP5 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators (PubMed:26375003, PubMed:26375259, PubMed:27418190). After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine (PubMed:27281216, PubMed:29898893, PubMed:36227980). Homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukin-1 (IL1B and IL18) and triggering pyroptosis (PubMed:27281216, PubMed:27418190, PubMed:29898893, PubMed:33883744, PubMed:38040708, PubMed:38530158, PubMed:38599239). Gasdermin pores also allow the release of mature caspase-7 (CASP7) (By similarity). In some, but not all, cells types, pyroptosis is followed by pyroptotic cell death, which is caused by downstream activation of ninjurin-1 (NINJ1), which mediates membrane rupture (cytolysis) (PubMed:33472215, PubMed:37198476). Also forms pores in the mitochondrial membrane, resulting in release of mitochondrial DNA (mtDNA) into the cytosol (By similarity). Gasdermin-D, N-terminal released from pyroptotic cells into the extracellular milieu rapidly binds to and kills both Gram-negative and Gram-positive bacteria, without harming neighboring mammalian cells, as it does not disrupt the plasma membrane from the outside due to lipid-binding specificity (PubMed:27281216). Under cell culture conditions, also active against intracellular bacteria, such as Listeria monocytogenes (By similarity). Also active in response to MAP3K7/TAK1 inactivation by Yersinia toxin YopJ, which triggers cleavage by CASP8 and subsequent activation (By similarity). Required for mucosal tissue defense against enteric pathogens (By similarity). Activation of the non-canonical inflammasome in brain endothelial cells can lead to excessive pyroptosis, leading to blood-brain barrier breakdown (By similarity). Strongly binds to bacterial and mitochondrial lipids, including cardiolipin (PubMed:27281216). Does not bind to unphosphorylated phosphatidylinositol, phosphatidylethanolamine nor phosphatidylcholine (PubMed:27281216).Gasdermin-D, p13Transcription coactivator produced by the cleavage by CASP3 or CASP7 in the upper small intestine in response to dietary antigens (By similarity). Required to maintain food tolerance in small intestine: translocates to the nucleus and acts as a coactivator for STAT1 to induce the transcription of CIITA and MHC class II molecules, which in turn induce type 1 regulatory T (Tr1) cells in upper small intestine (By similarity).Gasdermin-D, p40Produced by the cleavage by papain allergen (PubMed:35794369). After cleavage, moves to the plasma membrane and homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the specific release of mature interleukin-33 (IL33), promoting type 2 inflammatory immune response (PubMed:35794369).
DFNA5L, GSDMDC1, FKSG10, GSDMD, DFNA5L, GSDMDC1, FKSG10, Gasdermin-D, Gasdermin domain-containing protein 1
Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] ab215203 is a rabbit monoclonal antibody that is used in cleaved N-terminal GSDMD western blotting. Suitable for human samples.
- Recombinant format for unrivaled batch-batch consistency: no need for same-lot requests
- Antibody clone EPR20829-408 is cited in over 170 publications
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR20829-408
Affinity purification Protein A
The N-term cleaved Gasdermin-D needs inflammatory caspases in response to canonical and non-canonical inflammasome activators (PubMed: 31548300, PubMed: 27418190, PubMed: 26375259). If need to detect cleavage of GSDMD, please ensure that the samples are treated with inflammation before testing.
FURTHER INFORMATION ON SPECIFICITY (Chinese Version) available under the support & downloads section.
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
Cleaved N-terminal GSDMD also known as cleaved Gasdermin D is a protein fragment derived from the gasdermin D (GSDMD) molecule with an approximate molecular weight of 31-32 kDa. GSDMD is predominantly expressed in the cytosol of immune cells. Upon activation inflammasome pathways cause the cleavage of GSDMD into its active N-terminal fragment known as GSDMD-N. This cleavage is a critical event that translocates the cleaved form to the plasma membrane where it mediates its function.
The N-terminal fragment of cleaved GSDMD executes an important role in pyroptosis a type of programmed cell death. This fragment forms pores in the cell membrane allowing the release of pro-inflammatory cytokines. GSDMD does not act alone; it functions as part of a larger molecular complex often interacting with caspases like Caspase-1 and inflammatory molecules which enhance its role in immune responses. The formation of membrane pores by cleaved gasdermin D signifies its fundamental job in enabling cellular defense mechanisms against infections.
Cleaved N-terminal GSDMD participates in both pyroptosis and canonical inflammasome pathways. In the inflammasome pathway inflammasomes activate caspases that subsequently cleave GSDMD therefore linking it to a broad inflammatory response. This pathway involves proteins such as Caspase-1 and interleukin-1β which synergize with GSDMD to drive cytokine release. In addition GSDMD cleavage acts downstream of these interactions directly implementing pyroptotic cell death thereby contributing to the body’s innate immune defense.
Cleaved N-terminal GSDMD is notably linked to inflammatory conditions such as sepsis and inflammatory bowel disease. In sepsis the excessive activation of pyroptosis mediated by cleaved GSDMD leads to widespread inflammation and tissue damage. Cleaved GSDMD is also implicated in inflammatory bowel disease where dysregulation of the associated inflammation pathways causes chronic inflammation. In these conditions GSDMD's interaction with Caspase-1 and IL-1β amplifies the inflammatory responses underlining its potential as a target for therapeutic intervention in managing such diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
The lysate was kindly provided by our collaborator Dr Feng Shao's lab, NIBS.
The molecular weight observed is consistent with literature (PMID: 26375003).
Blocking/Dilution buffer: 5% NFDM/TBST.
The N-term cleaved Gasdermin-D needs inflammatory caspases in response to canonical and non-canonical inflammasome activators (PubMed: 31548300, PubMed: 27418190, PubMed: 26375259). If need to detect cleavage of GSDMD, please ensure that the samples are treated with inflammation before testing.
All lanes: Western blot - Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) at 1/1000 dilution
All lanes: Salmonella Infected (MOI:100) A431 (human epidermoid carcinoma cell line) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 53 kDa
Observed band size: 31 kDa
Exposure time: 3min
The lysate was kindly provided by our collaborator Dr Feng Shao's lab, NIBS.
The molecular weight observed is consistent with literature (PMID: 26375003).
Blocking/Dilution buffer: 5% NFDM/TBST.
The N-term cleaved Gasdermin-D needs inflammatory caspases in response to canonical and non-canonical inflammasome activators (PubMed: 31548300, PubMed: 27418190, PubMed: 26375259). If need to detect cleavage of GSDMD, please ensure that the samples are treated with inflammation before testing.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab215203).
The lysate was kindly provided by our collaborator Dr Feng Shao's lab, NIBS.
The molecular weight observed is consistent with literature (PMID: 26375003).
Blocking/Dilution buffer: 5% NFDM/TBST.
The N-term cleaved Gasdermin-D needs inflammatory caspases in response to canonical and non-canonical inflammasome activators (PubMed: 31548300, PubMed: 27418190, PubMed: 26375259). If need to detect cleavage of GSDMD, please ensure that the samples are treated with inflammation before testing.
All lanes: Western blot - Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) at 1/1000 dilution
Lane 1: Untreated THP-1 (human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2: THP-1 treated with 500 ng/ml EprI for 2h, whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 53 kDa
Observed band size: 31 kDa
Exposure time: 3min
ab215203 mainly recognizes N-terminal GSDMD and Anti-GSDMD antibody [EPR20859] ab219800 mainly recognizes full length GSDMD.
Exposure time: Lanes 1-4: 100 seconds, Lanes 5-6: 40 seconds.
Lanes 1 - 4: Western blot - Anti-cleaved N-terminal GSDMD antibody [EPR20829-408] (ab215203) at 1/1000 dilution
Lanes 5 - 6: Western blot - Anti-GSDMD antibody [EPR20859] (Anti-GSDMD antibody [EPR20859] ab219800) at 1/1000 dilution
Lanes 1, 3 and 5: Untreated THP-1 (human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lanes 2, 4 and 6: THP-1 (human epidermoid carcinoma cell line) treated with 50ng/ml TPA for 24 hours, then treated with 5ng/ml LPS for 3 hours and add 1µg/ml BFA for another 3 h whole cell lysate at 20 µg
Lanes 1, 2, 5 and 6: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Lanes 3 - 4: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/5000 dilution
Observed band size: 31 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com